Quantcast

Latest Adolor Corporation Stories

2009-02-18 15:41:00

- Conference Call Scheduled for February 25, 2009, 5:00 p.m.U.S. ET - EXTON, Pa., Feb. 18 /PRNewswire-FirstCall/ -- Adolor Corporation (Nasdaq: ADLR) today announced that it will hold a conference call at 5:00 p.m. ET on Wednesday, February 25, 2009 to discuss fourth quarter and year end financials and an update on the launch of ENTEREG(R) (alvimopan). To participate in the audio portion and have the opportunity to pose questions, dial (866) 394-4329 for domestic callers, or (706) 902-1952...

2008-09-02 09:00:43

Adolor Corporation (Nasdaq: ADLR) announced today that GlaxoSmithKline (GSK) has returned to Adolor worldwide rights related to Entereg(R) (alvimopan) for chronic opioid bowel dysfunction (OBD). GSK is retaining rights to Entereg for postoperative ileus (POI), and the companies will continue to collaborate on the development and commercialization of Entereg for POI in the United States. Adolor announced in July 2008 that the U. S. Food and Drug Administration (FDA) lifted the clinical...

2008-08-05 18:00:41

Adolor Corporation (Nasdaq:ADLR) today reported financial results for the three and six months ended June 30, 2008. For the three-month period ended June 30, 2008, the company reported net income of $7.5 million, or $0.16 per basic and diluted share, compared to a net loss of $11.6 million, or $0.25 per basic and diluted share, for the same period in 2007. For the six-month period ended June 30, 2008, the company reported a net loss of $1.6 million, or $0.03 per basic and diluted share,...

2008-07-24 09:01:13

Adolor Corporation (NASDAQ:ADLR) announced today that over 500 hospitals have now enrolled in the Entereg Access Support & Education (E.A.S.E.(TM)) Program. The Company estimates that these hospitals perform approximately 20% of the annual bowel resection procedures in the United States. The E.A.S.E. Program was launched by Adolor and GlaxoSmithKline (NYSE:GSK) in June 2008, following approval of Entereg(R) (alvimopan) capsules by the U.S. Food and Drug Administration in May. "We are...

2008-07-03 09:01:19

Adolor Corporation (Nasdaq: ADLR) today issued an update on the Entereg(R) (alvimopan) Program for chronic opioid bowel dysfunction (OBD), under development in collaboration with GlaxoSmithKline (NYSE: GSK). The U. S. Food and Drug Administration (FDA) has concluded that clinical investigations relating to alvimopan in OBD may now proceed, and has therefore lifted the clinical hold on the OBD Investigational New Drug Application. "After a productive meeting and dialogue with FDA, we...

2007-12-14 09:00:50

Adolor Corporation (Nasdaq: ADLR) announced today the initiation of a third Phase 2a study of ADL5859, a novel Delta opioid agonist in development for the treatment of pain. Study 33CL231 will explore the analgesic efficacy of ADL5859 in treating pain associated with diabetic peripheral neuropathy. Recently, Adolor and Pfizer Inc (NYSE: PFE) entered into a collaboration to develop and commercialize two Delta opioid agonist compounds, including ADL5859, for the treatment of a wide range...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related